MRAs in HFpEF & HFmrEF: A Clinical Debate

Are mineralocorticoid receptor antagonists (MRAs) ready for prime time in HFpEF and HFmrEF?

In this special debate-format episode of the Heart Failure Beat, two leading heart failure pharmacists, Stormi Gale, PharmD, BCCP, FHFSA and Robert L Page II, PharmD, MSPH, FHFSA, go head-to-head on steroidal vs non-steroidal MRAs.

From RALES and TOPCAT to FINEARTS-HF, they unpack the evidence, guideline implications, cost-effectiveness, CKM considerations, and real-world barriers to access. Is finerenone the “new pillar” in HFpEF? Or does spironolactone remain the practical, evidence-based choice? The conversation also explores phenotyping challenges in HF trials and whether combining SGLT2 inhibitors with MRAs can attenuate hyperkalemia risk.

If you care about precision medicine, cardiorenal overlap, or optimizing GDMT in complex patients, this debate is for you.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(51)

Listening to Classical Music May Help Patients with Heart Failure: Insights from a New Study and Soprano Renee Fleming

A music intervention from Italy involving daily listening of classical music selections was shown to improve quality of life and other outcomes in patients with chronic heart failure.

15 Syys 202026min

Evolving Approaches to Heart Failure Management in the COVID-19 Era

Evolving strategies for the management of heart failure in the context of COVID-19 are discussed with the lead authors of three papers published in the July issue of the Journal of Cardiac Failure.

5 Elo 202019min

Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19

Virtual Visits for the care of patients with heart failure in the era of COVID-19 and beyond -- best practices, policy changes, reimbursement, and more.

27 Huhti 202022min